FDA: Abbott's Trilipix may not lower heart, stroke risk; new trial ordered
This article was originally published in Scrip
Executive Summary
The US FDA said Abbott's cholesterol-lowering medicine Trilipix (fenofibric acid) may not lower a patient's risk of having a heart attack or stroke – coming to that conclusion long after the results were reported from the Action to Control Cardiovascular Risk in Diabetes (ACCORD)-Lipid trial – and ordered the company to conduct a new study.